Dovonex Psoriasis 50 microgram/g ointment * Pharmacy Only: Non-prescription
Company:
LEO PharmaStatus:
No Recent UpdateLegal Category:
Supply through pharmacy onlyActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 06 July 2020
File name
ie-mockup-pl dovonex psoriasis excip_1594025427.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 06 July 2020
File name
ie-spc clean dovonex psoriasis_1594024816.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
- In section 2 the quantity of propylene glycol has been added
- In section 4.8 the reporting of side effects statement has been updated in accordance with the latest version of Annex 5
Updated on 13 February 2020
File name
ie-pl-dovonex psoriasis ointment-paraffin_1581590509.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 6 - date of revision
- Addition of information on alternative format leaflets
Updated on 07 December 2016
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Updated on 07 December 2016
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 5.1 and 10 updated as follows;
5.1 Pharmacodynamic properties
ATC Code: D05A X02
Pharmacotherapeutic group: Other antipsoriatics for topical use
Calcipotriol is a vitamin D derivative. In vitro data suggest that calcipotriol induces differentiation and suppresses proliferation of keratinocytes. This is the proposed basis for its effect in psoriasis. A clinical improvement usually starts to become apparent after two weeks’ treatment.
10 DATE OF REVISION OF THE TEXT
April 2016 December 2016
Updated on 27 June 2016
File name
PIL_16733_458.pdf
Reasons for updating
- New PIL for new product
Updated on 27 June 2016
Reasons for updating
- Change to warnings or special precautions for use
- Change to date of revision
Updated on 17 May 2016
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 13 May 2016
Reasons for updating
- New PIL for new product